



Pharmaron Beijing Co., Ltd.  
康龍化成（北京）新藥技術股份有限公司  
(a joint stock company incorporated in the People's Republic of China with limited liability)  
(於中華人民共和國註冊成立的股份有限公司)  
(Stock Code 股份代號：3759)

NOTIFICATION LETTER 通知信函

Dear Non-registered holder<sup>(1)</sup>,

May 29, 2025

Pharmaron Beijing Co., Ltd. (the "Company")

– Notification of publication of (1) Circular of the 2024 Annual General Meeting & 2025 First H Share Class Meeting, (2) Notice of 2024 Annual General Meeting and (3) Notice of 2025 First H Share Class Meeting (the "Current Corporate Communication") on the website of the Company

The English version of the Company's Current Corporate Communication are available on the Company's website at [www.pharmaron.com](http://www.pharmaron.com) and the website of The Stock Exchange of Hong Kong Limited at [www.hkexnews.hk](http://www.hkexnews.hk) (the "HKEX's website"). You may access the Current Corporate Communication as appeared on the Company's website or browsing through the HKEX's website.

If you want to receive a printed version of the Current Corporate Communication and all future Corporate Communication<sup>(2)</sup>, please complete the request form (the "Request Form") on the reverse side and return it to the Company c/o the Company's H share registrar (the "H Share Registrar"), Tricor Investor Services Limited by using the mailing label at the bottom of the Request Form (a stamp is not required if posted in Hong Kong). The address of the H Share Registrar is 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong. The Request Form may also be downloaded from the Company's website at [www.pharmaron.com](http://www.pharmaron.com) or HKEX's website at [www.hkexnews.hk](http://www.hkexnews.hk).

Should you have any queries in relation to this letter, please call the Company's telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 5:00 p.m. from Monday to Friday, excluding Hong Kong public holidays or send an email to [3759-ecom@vistra.com](mailto:3759-ecom@vistra.com).

By order of the Board  
Pharmaron Beijing Co., Ltd.  
Dr. Lou Boliang  
Chairman

Notes:

- (1) This letter is addressed to Non-registered holders ("Non-registered holder" means such person or company whose shares are held in The Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited to receive Corporate Communication). If you have sold or transferred your H shares in the Company, please disregard this letter and the Request Form on the reverse side.
- (2) Corporate Communication means any document issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the annual report; (b) the interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

各位非登記持有人<sup>(1)</sup>：

康龍化成（北京）新藥技術股份有限公司（「本公司」）

— 於本公司網站刊發（一）2024年股東週年大會及2025年第一次H股類別股東大會之通函、（二）2024年股東週年大會通告及（三）2025年第一次H股類別股東大會通告（「本次公司通訊」）之發佈通知

本公司本次公司通訊的中文版本已上載於本公司的網站 [www.pharmaron.cn](http://www.pharmaron.cn) 和香港聯合交易所有限公司的網站 [www.hkexnews.hk](http://www.hkexnews.hk)（「聯交所網站」）。閣下可在本公司網站閱覽本次公司通訊或在聯交所網站瀏覽有關文件。

如閣下欲收取本次公司通訊及日後之公司通訊<sup>(2)</sup>的印刷本，請填妥在本函背面的申請表格（「申請表格」），並使用隨附之郵寄標籤寄回本公司H股股份過戶登記處（「H股股份過戶登記處」），卓佳證券登記有限公司（如在香港投寄則無須貼上郵票）。H股股份過戶登記處地址為香港夏慤道16號遠東金融中心17樓。申請表格亦可於本公司的網站 [www.pharmaron.cn](http://www.pharmaron.cn) 或聯交所網站 [www.hkexnews.hk](http://www.hkexnews.hk) 內下載。

如閣下對本函內容有任何疑問，請於星期一至星期五（香港公眾假期除外）上午9時正至下午5時正的辦公時間內致電本公司的電話熱線(852) 2980 1333或電郵至 [3759-ecom@vistra.com](mailto:3759-ecom@vistra.com)。

承董事會命  
康龍化成（北京）新藥技術股份有限公司  
主席  
樓柏良博士

2025年5月29日

附註：

- (1) 此函件乃向本公司之非登記持有人（「非登記持有人」指股份存放於中央結算及交收系統的人士或公司，透過香港中央結算有限公司不時向本公司發出通知，希望收到公司通訊）發出。如果閣下已經出售或轉讓所持有之本公司H股股份，則無需理會本函件及所附申請表格。
- (2) 「公司通訊」指本公司發出或將予發出以供其任何證券持有人參照或採取行動的任何文件，其中包括但不限於：(a)公司年度報告；(b)公司中期報告；(c)會議通告；(d)上市文件；(e)通函；及(f)委任代表表格。

## REQUEST FORM 申請表格

To: **Pharmaron Beijing Co., Ltd. (the "Company")**  
(Stock Code: 3759)  
c/o Tricor Investor Services Limited  
17/F, Far East Finance Centre  
16 Harcourt Road, Hong Kong

致: **康龍化成（北京）新藥技術股份有限公司**  
（「本公司」）  
（股份代號: 3759）  
經卓佳證券登記有限公司  
香港夏慤道16號  
遠東金融中心17樓

**I/We would like to receive the current and future Corporate Communications<sup>(1)</sup> of the Company as indicated below:**

**本人／吾等希望以下列方式索取本公司本次及今後刊發之公司通訊<sup>(1)</sup>：**

(Please mark "X" in ONLY ONE of the following boxes)

(請從下列選擇中，僅在其中一個空格內劃上「X」號)

- ☐ to receive a printed English version.  
僅收取一份英文印刷本。
- ☐ to receive a printed Chinese version.  
僅收取一份中文印刷本。
- ☐ to receive both the printed English and Chinese versions.  
同時收取英文及中文印刷本各一份。

Signature:

簽署: \_\_\_\_\_

Date:

日期: \_\_\_\_\_

Contact Phone Number:

聯絡電話: \_\_\_\_\_

Notes 附註:

- "Corporate Communications" refer to any document issued or to be issued by the Company for the information or action of holders of any of the Company's securities, including but not limited to: (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.  
「公司通訊」指由本公司發出或將予發出以供本公司任何證券的持有人參照或採取行動的任何文件，其中包括但不限於：(a)董事會報告、年度賬目連同核數師報告及財務摘要報告（如適用）；(b)中期報告及中期摘要報告（如適用）；(c)會議通告；(d)上市文件；(e)通函；及(f)代表委任表格。
- By completing and returning this Request Form to request for the printed copy of the Current Corporate Communication, you have expressly indicated that you prefer to receive all future Corporate Communications of the Company in printed copy.  
當閣下填寫及寄回此申請表格以索取刊發之本次公司通訊印刷本後，即表示閣下確認擬收取本公司日後刊發的所有公司通訊的印刷本。



### Mailing Label 郵寄標籤

Please cut the mailing label and stick it on an envelope to return the Request Form to us.  
**No postage stamp is required for local mailing**

當閣下寄回此表格時，請將郵寄標籤剪貼於信封上。  
如在本港投寄，閣下無需支付郵費或貼上郵票

**Tricor Investor Services Limited**  
**卓佳證券登記有限公司**  
**Freeport No. 簡便回郵號碼: 10 GPO**  
**Hong Kong 香港**  
**Pharmaron Beijing (3759)**